Adjuvant trastuzumab was allowed in women with HER2-positive tumours in TEXT, SOFT, and HOBOE; ABCSG XII predated the use of trastuzumab and HER2 status was not ascertained. This evidence concerns the gene ERBB2 and neoplasm.